Cybin Inc. – AMEX:CYBN
Cybin stock price today
$6.7
-2.45
-26.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Cybin stock price monthly change
+2759.38%
month
Cybin stock price quarterly change
+2759.38%
quarter
Cybin stock price yearly change
+2136.62%
year
Cybin key metrics
Market Cap | 189.02M |
Enterprise value | N/A |
P/E | -1.75 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 1.62 |
PEG ratio | 0.07 |
EPS | -0.22 |
Revenue | N/A |
EBITDA | -84.80M |
Income | -75.94M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCybin stock price history
Cybin stock forecast
Cybin financial statements
| Jun 2023 | 0 | -12.37M | |
|---|---|---|---|
| Sep 2023 | 0 | -11.89M | |
| Dec 2023 | 0 | -30.33M | |
| Mar 2024 | 0 | -21.34M |
| Mar 2024 | 0 | -21.34M | |
|---|---|---|---|
| Sep 2025 | 0 | -44.42M | |
| Dec 2025 | 0 | -44.42M | |
| Mar 2026 | 0 | -44.42M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.05 | -0.04 |
|---|---|---|
| 2024-02-14 | -0.02852 | -0.07 |
| 2024-06-26 | -0.02714 | -0.04 |
| Jun 2023 | 74590000 | 6.40M | 8.59% |
|---|---|---|---|
| Sep 2023 | 57627000 | 9.24M | 16.04% |
| Dec 2023 | 129723999 | 8.50M | 6.55% |
| Mar 2024 | 302023000 | 10.09M | 3.34% |
| Jun 2023 | -11.13M | -208K | 314K |
|---|---|---|---|
| Sep 2023 | -11.46M | -258K | 20.38M |
| Dec 2023 | -26.04M | 7.46M | 39.74M |
| Mar 2024 | -20.70M | -215K | 190.86M |
Cybin alternative data
| Aug 2023 | 50 |
|---|---|
| Sep 2023 | 50 |
| Oct 2023 | 50 |
| Nov 2023 | 50 |
| Dec 2023 | 50 |
| Jan 2024 | 50 |
| Feb 2024 | 50 |
| Mar 2024 | 50 |
| Apr 2024 | 50 |
| May 2024 | 50 |
| Jun 2024 | 50 |
| Jul 2024 | 50 |
Cybin other data
2.25%
-4.57%
of CYBN is owned by hedge funds
47
-16
3.75M
-7.64M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q3 2022 10 Feb 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Nov 2021 | Q2 2022 Earnings Call Transcript |
-
What's the price of Cybin stock today?
One share of Cybin stock can currently be purchased for approximately $6.7.
-
When is Cybin's next earnings date?
Unfortunately, Cybin's (CYBN) next earnings date is currently unknown.
-
Does Cybin pay dividends?
No, Cybin does not pay dividends.
-
How much money does Cybin make?
Cybin has a market capitalization of 189.02M. Cybin made a loss 78.08M US dollars in net income (profit) last year or -$0.04 on an earnings per share basis.
-
What is Cybin's stock symbol?
Cybin Inc. is traded on the AMEX under the ticker symbol "CYBN".
-
What is Cybin's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cybin?
Shares of Cybin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Cybin have?
As Jul 2024, Cybin employs 50 workers.
-
When Cybin went public?
Cybin Inc. is publicly traded company for more then 6 years since IPO on 13 Sep 2019.
-
What is Cybin's official website?
The official website for Cybin is cybin.com.
-
Where are Cybin's headquarters?
Cybin is headquartered at 100 King Street West, Toronto, ON.
-
How can i contact Cybin?
Cybin's mailing address is 100 King Street West, Toronto, ON and company can be reached via phone at +90 87648385.
Cybin company profile:
Cybin Inc.
cybin.comExchange:
AMEX
Full time employees:
50
Industry:
Biotechnology
Sector:
Healthcare
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
100 King Street West
Toronto, ON M5X 1C9
Toronto, ON M5X 1C9
CIK: 0001833141
ISIN: CA23256X1006
CUSIP: 23256X100
